At this BioBriefing Mark Sullivan, Founder, Managing Director and Board Member, Medicines Development for Global Health (MDGH) and recently announced Victorian Australian of the Year 2019 will be talking to the Network about how he has brought the drug Moxidectin, which treats river blindness, to market. MDGH is the first not-for-profit company to register a medicine through the tropical disease Priority Review Voucher (PRV) program.
Also speaking will be Jennifer Herz, Managing Director, Biointelect and Director, 60P Australia, who will be similarly sharing her journey with Kodatef (tafenoquine), for prevention of malaria for travellers to endemic areas. Tafenoquine was granted Priority Review and has recently been approved by both the FDA and TGA, the first new approval for malaria prevention in over 20 years.
Date: Tuesday, 27 November 2018
Time: 3.45 pm registration, 4.00 pm–5.15 pm BioBriefing, 5.15 pm–6.30 pm networking
Venue: Phillips Ormonde Fitzpatrick, Level 16, 333 Collins Street, Melbourne
Price: $65 BioMelbourne Network members; $130 non-members (Prices include GST; check if your organisation is a member here)
This event is kindly sponsored by:
Read more about our speakers:
Mark Sullivan, Founder, Managing Director and Board Member, Medicines Development for Global Health
Founder and Managing Director of Medicines Development, a biopharmaceutical company focusing on developing and delivering medicines for diseases of low- and middle-income countries. Key career highlights include 11 years executive management, Advisory Board, and Board of Directors experience in biotechnology and 28 years’ experience in clinical development within biotechnology, large pharmaceutical, contract services, and academic sectors. Drug development experience encompasses project leadership of 5 products, including moxidectin for the treatment of onchocerciasis, and extensive practical experience of implementation of clinical first exposure, proof of concept, phase 2, global phase 3, phase 3b design and implementation, and phase 4 clinical studies. Significant contributor to 3 successful global registrational programs. Chief Operating Officer of Australia’s HIV vaccine design and development consortium responsible for designing, constructing, manufacturing and clinically evaluating a novel HIV vaccine. Extensive international experience having worked in operating company (UK 4 years), international head office (UK 6 years, US 2 years), contract research (Australia 1 year), and academic settings (Australia 3 years) with direct experience of drug development in 24 countries.
Jennifer Herz, Managing Director, Biointelect and Director, 60P Australia
Jennifer Herz founded Biointelect in 2011 to provide strategic commercialisation services to the biopharmaceutical industry. She has over 20 years of commercial, business development and scientific affairs experience in the biopharmaceutical industry and has held a variety of roles with responsibility for Australia, New Zealand and European markets. Jennifer was the first Managing Director of Sanofi Pasteur in Australia which was a start-up company and grew significantly over the six years of her tenure to be an established major provider of vaccines to the public and private market in Australia, New Zealand and the Pacific Region. She is a member of the Accelerate Commercialisation Expert Network, on the Steering Committee of the NHMRC funded Centre of Research Excellence: Policy relevant infectious disease simulation and mathematical modelling (PRISM) and is a member of the Expert Reference Group of the Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE).
Biointelect has an extensive international & local network of industry, policy, scientific and clinical experts across many therapeutic areas and healthcare sectors along with global experience in multiple new product launches and start-ups at all stages of development. Since 2012 we have delivered over 130 projects to more than 50 clients supporting the commercialisation of novel health technologies.